NSEI:FDC

Stock Analysis Report

Executive Summary

FDC Limited manufactures and markets pharmaceutical products in India and internationally.


Snowflake Analysis

Flawless balance sheet with acceptable track record.

Share Price & News

How has FDC's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: FDC's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.0%

FDC

-0.4%

IN Pharmaceuticals

-0.3%

IN Market


1 Year Return

42.6%

FDC

-1.7%

IN Pharmaceuticals

9.9%

IN Market

Return vs Industry: FDC exceeded the Indian Pharmaceuticals industry which returned -5.2% over the past year.

Return vs Market: FDC exceeded the Indian Market which returned 6.7% over the past year.


Shareholder returns

FDCIndustryMarket
7 Day-1.0%-0.4%-0.3%
30 Day9.5%4.6%3.5%
90 Day34.0%8.2%5.9%
1 Year42.6%42.6%-0.6%-1.7%11.9%9.9%
3 Year5.2%3.9%-9.7%-11.7%30.2%23.3%
5 Year43.5%38.5%-13.3%-16.0%37.1%24.8%

Price Volatility Vs. Market

How volatile is FDC's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is FDC undervalued compared to its fair value and its price relative to the market?

20.84x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: FDC (₹229.25) is trading above our estimate of fair value (₹128.39)

Significantly Below Fair Value: FDC is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: FDC is poor value based on its PE Ratio (20.8x) compared to the Pharmaceuticals industry average (16.4x).

PE vs Market: FDC is poor value based on its PE Ratio (20.8x) compared to the Indian market (13.8x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate FDC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: FDC is overvalued based on its PB Ratio (2.8x) compared to the IN Pharmaceuticals industry average (1.5x).


Next Steps

Future Growth

How is FDC forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

12.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as FDC has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has FDC performed over the past 5 years?

3.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: FDC has high quality earnings.

Growing Profit Margin: FDC's current net profit margins (15.7%) are lower than last year (15.9%).


Past Earnings Growth Analysis

Earnings Trend: FDC's earnings have grown by 3.1% per year over the past 5 years.

Accelerating Growth: FDC's earnings growth over the past year (11.2%) exceeds its 5-year average (3.1% per year).

Earnings vs Industry: FDC earnings growth over the past year (11.2%) underperformed the Pharmaceuticals industry 19.2%.


Return on Equity

High ROE: FDC's Return on Equity (13.3%) is considered low.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is FDC's financial position?


Financial Position Analysis

Short Term Liabilities: FDC's short term assets (₹8.1B) exceed its short term liabilities (₹2.5B).

Long Term Liabilities: FDC's short term assets (₹8.1B) exceed its long term liabilities (₹239.4M).


Debt to Equity History and Analysis

Debt Level: FDC's debt to equity ratio (0.02%) is considered satisfactory.

Reducing Debt: FDC's debt to equity ratio has reduced from 0.3% to 0.02% over the past 5 years.

Debt Coverage: FDC's debt is well covered by operating cash flow (50590.2%).

Interest Coverage: FDC earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: FDC has a high level of physical assets or inventory.

Debt Coverage by Assets: FDC's debt is covered by short term assets (assets are 2371.9x debt).


Next Steps

Dividend

What is FDC's current dividend yield, its reliability and sustainability?

1.09%

Forecast Dividend Yield


Dividend Yield vs Market

company0%marketbottom25%0.5%markettop25%2.3%industryaverage0.8%forecastin3Years1.1%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate FDC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate FDC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if FDC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FDC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: FDC is not paying a notable dividend for the Indian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of FDC's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

What is the CEO of FDC's salary, the management and board of directors tenure and is there insider trading?

15.8yrs

Average management tenure


CEO

Nandan Chandavarkar 0

15.8yrs

Tenure

₹17,468,229

Compensation

Dr. Nandan Mohan Chandavarkar has been Joint Managing Director of FDC Limited since March 1, 2004 and serves as its Executive Director. Dr. Chandavarkar has been a Director at FDC International Ltd. since  ...


CEO Compensation Analysis

Compensation vs Market: Nandan's total compensation ($USD246.50K) is below average for companies of similar size in the Indian market ($USD402.62K).

Compensation vs Earnings: Nandan's compensation has been consistent with company performance over the past year.


Management Age and Tenure

15.8yrs

Average Tenure

Experienced Management: FDC's management team is seasoned and experienced (15.8 years average tenure).


Board Age and Tenure

3.0yrs

Average Tenure

Experienced Board: FDC's board of directors are considered experienced (3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Nandan Chandavarkar

    Joint MD & Executive Director

    • Tenure: 15.8yrs
    • Compensation: ₹17.47m
  • Mohan Chandavarkar

    MD & Director

    • Compensation: ₹21.89m
  • Ameya Chandavarkar

    Executive Director

    • Tenure: 10.2yrs
    • Compensation: ₹12.12m
  • Ashok Chandavarkar

    Executive Director

    • Tenure: 10.2yrs
    • Compensation: ₹14.87m
  • Nomita Chandavarkar

    Executive Director

    • Tenure: 5.6yrs
    • Compensation: ₹5.88m
  • Varsharani Katre

    Compliance Officer & Company Secretary

    • Sanjay Jain

      Chief Financial Officer

      • Tenure: 6.3yrs
    • Dilip Karnik (67yo)

      President of Technical & Operations


      Board Members

      • Nandan Chandavarkar

        Joint MD & Executive Director

        • Tenure: 15.8yrs
        • Compensation: ₹17.47m
      • Mohan Chandavarkar

        MD & Director

        • Compensation: ₹21.89m
      • Ameya Chandavarkar

        Executive Director

        • Tenure: 10.2yrs
        • Compensation: ₹12.12m
      • Ashok Chandavarkar

        Executive Director

        • Tenure: 10.2yrs
        • Compensation: ₹14.87m
      • Nomita Chandavarkar

        Executive Director

        • Tenure: 5.6yrs
        • Compensation: ₹5.88m
      • Swati Mayekar (62yo)

        Independent & Non Executive Director

        • Tenure: 5.3yrs
        • Compensation: ₹340.00k
      • Uday Gurkar

        Independent Chairman of the Board

        • Tenure: 0.8yrs
        • Compensation: ₹305.00k
      • Mahesh Bijlani

        Additional Non-Executive & Independent Director

        • Tenure: 0.7yrs
      • Usha Chandrasekhar

        Additional Non-Executive & Independent Director

        • Tenure: 0.7yrs
      • Melarkode Parameswaran

        Additional Non-Executive & Independent Director

        • Tenure: 0.7yrs

      Company Information

      FDC Limited's company bio, employee growth, exchange listings and data sources


      Key Information

      • Name: FDC Limited
      • Ticker: FDC
      • Exchange: NSEI
      • Founded: 1936
      • Industry: Pharmaceuticals
      • Sector: Pharmaceuticals & Biotech
      • Market Cap: ₹39.281b
      • Shares outstanding: 170.97m
      • Website: https://www.fdcindia.com

      Location

      • FDC Limited
      • 142-48, Swami Vivekananda Road
      • Jogeshwari (West)
      • Mumbai
      • Maharashtra
      • 400102
      • India

      Listings

      TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
      531599BSE (Mumbai Stock Exchange)YesEquity SharesININRJul 1997
      FDCNSEI (National Stock Exchange of India)YesEquity SharesININRJul 1997

      Biography

      FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmological, vitamins/minerals/dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics, and others; and oral rehydration salts. It provides specialized formulations primarily under the Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl, and Mycoderm brand names. The company also offers anti-oxidants, balanced energy drinks, and vitamins and nutraceuticals under the MMO3, Enerzal, Humyl, Mum Mum 1, Prosoyal, Simyl-LBW, Simyl-MCT, and Zefrich brands. In addition, it provides various active pharmaceutical ingredients. The company was founded in 1936 and is headquartered in Mumbai, India. 


      Company Analysis and Financial Data Status

      All financial data provided by Standard & Poor's Capital IQ.
      DataLast Updated (UTC time)
      Company Analysis2020/01/26 13:01
      End of Day Share Price2020/01/24 00:00
      Earnings2019/09/30
      Annual Earnings2019/03/31


      Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.